Book Navigation
 

International guideline library update

New in the International Guideline Library – December 2011 to 2 April 2012

Organisation

Title

AAO-HNS (US)

Clinical Practice Guideline: Sudden Hearing Loss

ACCP (US)

Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-based Clinical Practice Guidelines, 9th Edition

AWMF (DE)

Diagnostik von Sprachentwicklungsstörungen (SES) unter Berücksichtigung umschriebener Sprachentwicklungsstörungen (USES). S2k-LL (DGKJP/DGPP/DGKJ)
[Diagnosis of developmental language disorders in consideration of specific developmental language disorders]

AWMF (DE)

Diagnostik und antientzündliche Therapie der Uveitis bei juveniler idiopathischer Arthritis. S2k-LL (DOG, DGRh, GKJR)
[Diagnosis and anti-inflammatory treatment for uveitis in juvenile idiopathic arthritis]

AWMF (DE)

Intraartikuläre Frakturen des distalen Humerus im Kindesalter. S2k-LL (DGKCH, DGOOC, DGU)
[T-condylar fractures of the distal humerus in children and adolescents]

DKG (DE)

Diagnostik, Therapie, Nachsorge des Adenokarzinoms des Magens und gastro-ösophagealen Übergangs (kurz: Magenkarzinom) (Leitlinienprogramm Onkologie von AWMF, DKG und DKH)
[Diagnosis, treatment, aftercare of adenocarcinoma of the stomach and gastro-oesophageal junction]

DM (BE)

Aanvraag van laboratoriumtests door huisartsen (deel 1)
[Request for laboratory determinations by general practitioners]

HAS (FR)

Autisme et autres troubles envahissants du développement: interventions éducatives et thérapeutiques coordonnées chez l’enfant et l’adolescent. Consensus formalisé
[Autism and other severe developmental disorders: treatment of children and adolescents]

HAS (FR) Syndrome de Prader-Willi. Guide ALD
Hdir (NO)

Nasjonal faglig retningslinje for utredning, behandling og oppfølging av personer med samtidig ruslidelse og psykisk lidelse – ROP-lidelser
[National guideline for assessment, treatment and care of persons with addictions and mental illness]

IDSA (US)

IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults

IQWiG (DE)

Abirateronacetat - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Addendum zum Abschlussbericht A09-02 (Nutzenbewertung von Prasugrel)
[Addendum to the final report A09-02 (benefit assessment of prasugrel)]

IQWiG (DE)

Aliskiren/Amlodipin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Aliskiren/amlodipine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Apixaban – Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Aussagekraft von Surrogatendpunkten in der Onkologie (Rapid Report)
[Validity of surrogate endpoints in oncology]

IQWiG (DE)

Cabazitaxel - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Eribulin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Fingolimod - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Linagliptin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Pirfenidon: Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Pirfenidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Retigabin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Retigabine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Stammzelltransplantation bei Multiplem Myelom
[Stem cell transplantation for multiple myeloma]

IQWiG (DE)

Systematische Leitlinienrecherche und -bewertung sowie Extraktion neuer und relevanter Empfehlungen für das DMP Diabetes mellitus Typ 2
[Systematic guideline search and appraisal for the DMP diabetes mellitus type 2 and extraction of new, relevant recommendations]

IQWiG (DE)

Tafamidis - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Tafamidis - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Telaprevir - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Telaprevir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

MoH (SG) Depression
NICE (GB) Anaphylaxis (CG134)

NICE (GB)

Epilepsy (CG137)

NICE (GB)

Infection control (CG139)

NICE (GB)

Organ donation (CG135)

NICE (GB)

Patient experience in adult NHS services (CG138)

NICE (GB)

Service user experience in adult mental health (CG136)

NICE (GB)

Tuberculosis - hard to reach groups (PH37)
SIGN (GB)

Diagnosis and management of colorectal cancer (SIGN CPG 126)

 
enGINe Newsletter

Subscribe here to the enGINe Newsletter.


Page last updated: Apr 11, 2012
Copyright © 2002-2016 Guidelines International Network.
All rights reserved

The Guidelines International Network is formally constituted as a Scottish Guarantee Company under Company Number SC243691 and recognised as a Scottish Charity under Scottish Charity Number SC034047 with its Registered Office at J. & H. Mitchell W.S., 51 Atholl Road, Pitlochry, Perthshire PH16 5BU, Scotland.

Back to top